Jubilant Ingrevia Ltd

Jubilant Ingrevia Expands into Pharma & Nutrition with Strategic Acquisition 📈

- Acquired 100% stake in Remidex Pharma (₹1,628 lakhs) to expand into human nutrition & pharmaceutical manufacturing (effective March 30, 2026).

- Consolidated FY26 revenue: ₹4,38,807 lakhs (vs. ₹4,17,761 lakhs in FY25).

- FY26 net profit (attributable to owners): ₹27,791 lakhs (vs. ₹25,117 lakhs in FY25).

- Recommended final dividend: ₹2.5/share (total ₹3,982 lakhs), bringing FY26 total dividend to ₹5/share.

- New Labour Codes led to exceptional expense of ₹1,304 lakhs due to employee benefit changes.

- Strong financial position: Debt-equity ratio of 0.19x, net worth of ₹3,12,622 lakhs as of March 31, 2026.

- Debt service coverage ratio: 4.39x; interest service coverage ratio: 12.36x.